| mRNA |
sirolimus:bortezomib (250:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
-0.0026 |
0.9 |
| mRNA |
Topotecan |
FIMM |
pan-cancer |
AAC |
0.0084 |
0.9 |
| mRNA |
BRD-K51831558 |
CTRPv2 |
pan-cancer |
AAC |
-0.0038 |
0.9 |
| mRNA |
BRD9647 |
CTRPv2 |
pan-cancer |
AAC |
-0.0026 |
0.9 |
| mRNA |
ML311 |
CTRPv2 |
pan-cancer |
AAC |
-0.0022 |
0.9 |
| mRNA |
selumetinib:decitabine (4:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
-0.0023 |
0.9 |
| mRNA |
Teniposide |
CTRPv2 |
pan-cancer |
AAC |
0.0028 |
0.9 |
| mRNA |
navitoclax:gemcitabine (1:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.0022 |
0.9 |
| mRNA |
Curcumin |
CTRPv2 |
pan-cancer |
AAC |
0.0022 |
0.9 |
| mRNA |
PD-0332991 |
CCLE |
pan-cancer |
AAC |
-0.003 |
1 |